{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:16:56Z","timestamp":1790691416076,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jconrel.2018.12.048","type":"journal-article","created":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T02:15:50Z","timestamp":1546222550000},"page":"93-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"special_numbering":"C","title":["Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer"],"prefix":"10.1016","volume":"295","author":[{"given":"Tovi","family":"Shapira-Furman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Gorelick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Doglioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arba","family":"Cecia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0900-8231","authenticated-orcid":false,"given":"Michael","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awanish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakir","family":"Rottenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Brem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9800-6969","authenticated-orcid":false,"given":"Betty","family":"Tyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham J.","family":"Domb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2018.12.048_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","article-title":"Overcoming the blood\u2013brain tumor barrier for effective glioblastoma treatment","volume":"19","author":"van Tellingen","year":"2015","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0010","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1158\/1055-9965.EPI-14-0275","article-title":"Epidemiologic and molecular prognostic review of glioblastoma","volume":"23","author":"Thakkar","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0015","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00401-010-0736-4","article-title":"Molecular diagnostics of gliomas: state of the art","volume":"120","author":"Riemenschneider","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0020","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3171\/2008.5.17557","article-title":"Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme","volume":"110","author":"McGirt","year":"2009","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0025","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.biopha.2017.05.125","article-title":"Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: a review","volume":"92","author":"Anjum","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0030","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0035","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bjc.1992.57","article-title":"Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)","volume":"65","author":"Newlands","year":"1992","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2018.12.048_bb0040","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijpharm.2006.08.027","article-title":"Temozolomide\/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro","volume":"329","author":"Zhang","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0045","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11060-009-9980-7","article-title":"Extended-schedule dose-dense temozolomide in refractory gliomas","volume":"96","author":"Berrocal","year":"2010","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0050","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ijpharm.2007.12.013","article-title":"Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity","volume":"355","author":"Huang","year":"2008","journal-title":"Int. J. Pharmac."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0055","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.canlet.2015.08.022","article-title":"Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma","volume":"369","author":"Kim","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0060","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2174\/092986709787002718","article-title":"Recent approaches to improve the antitumor efficacy of temozolomide","volume":"16","author":"Tentori","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0065","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/OTT.S120662","article-title":"Strategies of temozolomide in future glioblastoma treatment","volume":"10","author":"Lee","year":"2017","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0070","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/1061186X.2017.1379526","article-title":"Controlled release of liposome-encapsulated temozolomide for brain tumour treatment by convection-enhanced delivery","volume":"26","author":"Lin","year":"2018","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0075","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2017.06.028","article-title":"Liposomal temozolomide drug delivery using convection enhanced delivery","volume":"261","author":"Nordling-David","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.12.048_bb0080","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.nantod.2014.04.008","article-title":"Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects","volume":"9","author":"Barua","year":"2014","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2018.12.048_bb0085","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0168-3659(96)01371-5","article-title":"Effects of GLIADEL\u00ae wafer initial molecular weight on the erosion of wafer and release of BCNU","volume":"42","author":"Dang","year":"1996","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.12.048_bb0090","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd1414","article-title":"Targeted therapy for brain tumours","volume":"3","author":"Lesniak","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0095","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/neuonc\/5.2.79","article-title":"A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma","volume":"5","author":"Westphal","year":"2003","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jconrel.2018.12.048_bb0100","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11060-015-1724-2","article-title":"Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis","volume":"122","author":"Chowdhary","year":"2015","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0105","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(95)90755-6","article-title":"Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas","volume":"345","author":"Brem","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2018.12.048_bb0110","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/cpt.71","article-title":"Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood\u2013brain barrier","volume":"97","author":"Parrish","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0115","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/ph9030054","article-title":"Preparation of temozolomide-loaded nanoparticles for glioblastoma multiforme targeting\u2014ideal versus reality","volume":"9","author":"Lee","year":"2016","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2018.12.048_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2008-2231-22-18","article-title":"Unraveling the cytotoxic potential of temozolomide loaded into PLGA nanoparticles","volume":"22","author":"Jain","year":"2014","journal-title":"Daru"},{"key":"10.1016\/j.jconrel.2018.12.048_bb0125","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijpharm.2012.03.047","article-title":"Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma","volume":"430","author":"Ling","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0130","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3171\/jns.1991.74.3.0441","article-title":"Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas","volume":"74","author":"Brem","year":"1991","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0135","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0169-409X(02)00050-9","article-title":"Polyanhydrides: an overview","volume":"54","author":"Kumar","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0140","first-page":"5103","article-title":"Controlled delivery of 1,3-bis(2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate copolymer","volume":"49","author":"Yang","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4236\/jbnb.2015.61002","article-title":"Synthesis, characterization, and study of PLGA copolymer in vitro degradation","volume":"6","author":"Silva","year":"2015","journal-title":"J. Biomater. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0150","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers"},{"key":"10.1016\/j.jconrel.2018.12.048_bb0155","doi-asserted-by":"crossref","first-page":"28219","DOI":"10.1039\/C5RA03871E","article-title":"In vitro and in vivo studies of temozolomide loading in zeolite structures as drug delivery systems for glioblastoma","volume":"5","author":"Martinhoab","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0160","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jelechem.2013.07.011","article-title":"Temozolomide chemical degradation to 5-aminoimidazole4-carboxamide\u2013Electrochemical study","volume":"704","author":"Lopes","year":"2013","journal-title":"J. Electroanal. Chem."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0165","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0142-9612(95)93260-K","article-title":"In vivo and in vitro elimination of aliphatic polyanhydrides","volume":"16","author":"Domb","year":"1995","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.12.048_bb0170","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neo.2017.02.009","article-title":"Inhibitors of GLUT\/SLC2A enhance the action of BCNU and temozolomide against high-grade gliomas","volume":"19","author":"Azzalin","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.jconrel.2018.12.048_bb0175","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1227\/01.NEU.0000365263.14725.39","article-title":"Combination of intracranial Temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent Glioma model","volume":"66","author":"Recinos","year":"2010","journal-title":"Neurosurgery"},{"key":"10.1016\/j.jconrel.2018.12.048_bb0180","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4155\/tde.14.114","article-title":"Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas","volume":"6","author":"Chaichana","year":"2015","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0185","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1080\/17425247.2016.1193153","article-title":"Advanced interstitial chemotherapy for treating malignant glioma","volume":"13","author":"Tseng","year":"2016","journal-title":"Exp. Opin. Drug. Del."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0190","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/00003088-200241060-00002","article-title":"Pharmacokinetics of the carmustine implant","volume":"41","author":"Fleming","year":"2002","journal-title":"Clin. Pharmacok."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0195","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00280-006-0407-2","article-title":"Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model","volume":"60","author":"Brem","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0200","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.2174\/0929867323666161014132907","article-title":"Current and future drug treatments for glioblastomas","volume":"23","author":"Ohba","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2018.12.048_bb0205","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/PPO.0b013e318244d8ae","article-title":"Novel delivery strategies for glioblastoma","volume":"18","author":"Zhou","year":"2012","journal-title":"Cancer J."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918307533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918307533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T07:06:14Z","timestamp":1548831974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365918307533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":41,"alternative-id":["S0168365918307533"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.12.048","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.12.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}